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Abstract. The effect of corticosteroids upon the cortisol 
response to nicotine from smoking was investigated in 
five heavy smokers. Corticosteroid activity was manipu- 
lated by administering dexamethasone, a synthetic gtu- 
cocortoicoid (1 mg orally, 14 h before), in a double- 
blind, placebo-controlled procedure. Testing took place 
in the middle of the day and involved the smoking of 
two high-nicotine (2.87 nag) research cigarettes over a 
15-rain period. The dexamethasone condition was char- 
acterized by a pronounced suppression of baseline plas- 
ma cortisol, as expected, and by a significant dampening 
of the cortisol response to nicotine, indicating dimin- 
ished sensitivity to nicotine under conditions of en- 
hanced corticosteroid activity. 
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Acute intake of nicotine by cigarette smoking increases 
adrenocorticotrophic hormone (ACTH) and cortisol lev- 
els in circulation in a dose-related manner (Cryer et al. 
1976; Winternitz and Quillen 1977; Wilkins et at. 1982; 
Chiodera et al. 1984; Seyler et al. 1984; Pomerleau and 
Pomerleau 1988). In animals, nicotine has been shown 
to stimulate corticotropin releasing factor (CRF) from 
the hypothalamus via a nicotinic cholinergic pathway 
(Hillhouse et al. 1975; Weidenfeld et al. 1983), and direct 
application of nicotine to the hypothalamus significantly 
increases levels of ACTH (Marry et al. 1985) and corti- 
costerone (Conte-Devolx et al. 1981). 
Recent studies on corticosteroid modulation of sensi- 
tivity to nicotine may shed light on the functional signifi- 
cance of the above observations. Using inbred mice, 
Freund et al. (1988) demonstrated consistent strain dif- 
ferences in the corticosterone response to nicotine that 
Offprint requests to: O.F. Pomerleau 
were paralleled by behavioral and physiological differ- 
ences in sensitivity to nicotine. In related research, Pauly 
et al. (1988) found that after adrenalectomy, mice exhib- 
ited low corticosterone levels and greater sensitivity to 
the behavioral and physiological effects of nicotine; this 
effect did not appear to be mediated by rate of nicotine 
metabolism or differences in number or affinity of brain 
nicotinic receptors. Administration of exogenous corti- 
costerone fhlly restored protection from nicotine's ef- 
fects in all response systems measured (Y-maze rears, 
heart rate, startle response, and core temperature). Pauly 
et al. concluded that corticosteroid activity modulates 
sensitivity to nicotine as part of a negative feedback sys- 
tem that affects nicotinic receptors by a mechanism of 
action that is not yet understood. 
It has been suggested that in humans, cortisol, a glu- 
cocorticoid, has subsumed most of the functions served 
by corticosterone, a mineralocorticoid with some gluco- 
corticoid activity, in mice and rats (De Kloet et al. 1987). 
In the present study, corticosteroid levels were manipu- 
lated by administering dexamethasone (DEX), a synthet- 
ic glucocorticoid. The magnitude of cortisol stimulation 
by nicotine was used as a marker of sensitivity to nico- 
tine. We hypothesized that DEX administration, by in- 
creasing overall corticosteroid activity, would diminish 
sensitivity to nicotine. 
Materials and methods 
Five male heavy smokers (smoking more than 20 cigarettes per 
day for at least 5 years), in otherwise good health and not on 
medications, participated in the study. Mean age was 46.4___6.4 
(SEM) years. They had smoked for 30.0 + 6.2 years and reported 
smoking a mean of 34.0_+2.9 cigarettes per day. Mean score on 
the Fagerstrom Tolerance Questionnaire was 8.0 +0.0 and mean 
plasma cotinine level 359_+40.9 rig/rot, characterizing the subjects 
as highly nicotine-dependent. Subjects were given the Beck Depres- 
sion Inventory to screen for depression (which is sometimes asso- 
ciated with failure to suppress cortisol levels in response to dexa- 
methasone administration; Carotl 1978); scores ranged from 1 to 
16. 
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Each subject participated in two sessions. Subjects were given 
a tablet and instructed to take it at 2300 hours the night before 
a session. Tablets were either DEX (1 rag) or placebo, given in 
counterbalanced order using a double blind protocol. Subjects were 
asked to arrive at 1200 hours on the following day, having eaten 
a standardized breakfast but no lunch and having smoked ad libi- 
tum during the morning. They sat in an easy chair, near a console 
that dispensed cigarettes and signaled the start of a smoking inter- 
val. A neutral movie ("The Sound of Music") was shown on a 
VCR. Subjects were permitted to smoke one own-brand cigarette 
and then asked not to smoke until the experimental session began. 
One hour later, a line was inserted in a forearm vein for sam- 
pling of plasma nicotine and cortisol levels. After waiting 20 rain 
to allow cortisol levels to normalize following venipuncture, blood 
sampling (over a 30-s period) began. Following 5 rain of baseline 
measures, subjects were asked to smoke a high-nicotine research 
cigarette (University of Kentucky Tobacco and Health Research 
Institute IA4; yield 2.9 mg) over a 5-min interval (min 5 to rain 10); 
folIowing a 5-min rest (rain 10 to rain 15), they were asked to smoke 
a second cigarette (rain 15 to min 20). Blood samples were with- 
drawn at min 0, 5, 10, 20, 30, 40 and 55. 
Samples were analyzed for nicotine and cortisol in plasma using 
RIA (see Seyler et al. 1984). Statistical analyses involving repeated 
measures ANOVA and ANCOVA were carried out using 
BMDP2V. Since uni-directional hypotheses were specified, all sta- 
tistical probabilities reported are one-tailed. 
Results 
All subjects showed profound baseline depressions of  
cortisol in the D E X  condition (Martin and Reichlin 
1987), confirming compliance with instructions to self- 
administer the tablets. 
Time course for plasma cortisol over the two condi- 
tions is shown in Fig. 1. A 2 (DEX versus p lacebo)x  7 
(time points) A N O V A  was conducted. A significant time 
effect [F(6,24 = 3.88, P = 0.0038], with a significant linear 
trend [F(1,4)=4.79, P=0.0470] ,  was revealed, showing 
the effect o f  nicotine upon cortisol; a highly significant 
D E X  effect [F(1,4)=60.09, P=0.0008]  was also seen, 
as expected. A significant interaction effect [F(6,24)= 
3.38, P=0.0084] ,  apparent ly attributable to the atten- 
uating effects o f  D E X  upon the cortisol response, was 
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Fig. 1. Mean plasma cortisol levels before and after smoking two 
high-nicotine (2.9 mg) cigarettes, approximately 14 h after adminis- 
tration of placebo or dexamethasone (1 mg); mean ± SEM; N= 5. 
o-o  Placebo; e - e  dexamethasone 
Table 1. Baseline (minute 0), peak (maximal value), and change 
in cortisol levels (pg/t00 ml) for placebo and dexamethosone condi- 
tions 
Sub- Placebo DEX 
ject 
Baseline Peak Change Baseline Peak Change 
1 6.5 9.7 3.2 0.0 0.0 0.0 
2 16.2 19.9 3.7 2.0 4.0 2.0 
3 7.3 7.4 0.1 0.6 0.7 0.1 
4 7.9 14.7 6.8 0.9 4.9 4.0 
5 6.5 9.9 3.4 1.3 1.1 -0.2 
R 8.9 12.3 3.4 1.0 2.1 1.2 
SEM ±1.8 ±2.2 ±1.1 ±0.3 ±1.0 ±0.8 
In order to focus more clearly on the cortisol re- 
sponse to nicotine administration, peak post-smoking 
values were calculated as shown in Table 1 ; as can be 
seen, four of  the five subjects exhibited greater stimula- 
tion of  cortisol by nicotine in the placebo condition than 
the DEX condition; the fifth showed the same increase 
for both  conditions. A one-way A N O V A  with four lev- 
els of  time (min 0/placebo, rain 0/DEX, peak/placebo,  
and peak /DEX)  was conducted; using the Bonferroni 
statistic, it was established that peak values were signifi- 
cantly higher than baseline (min 0) values for the place- 
bo condition (P < 0.05) but not for the D E X  condition. 
In order to take into account individual differences in 
nicotine intake in the two conditions, cortisol change 
per unit nicotine increment was also computed,  and 
again significantly higher changes were found for the 
placebo condition than for the D E X  condition (t = 2.65, 
P =  0.0286). Subjects showed a tendency towards a char- 
acteristic cortisol response to nicotine, as indicated by 
a Pearson correlation coefficient of  0.796 (P=0.0537)  
between cortisol changes on the placebo day and on 
the D E X  day. 
In the D E X  condition, the mean plasma nicotine pre- 
smoking level was 14.4_+2.0 ng/ml and the peak post- 
smoking level was 34.1 -t- 4.0 ng/ml; in the placebo condi- 
tion, the pre-smoking level was 14.4 + 3.0 ng/ml and the 
peak post-smoking level was 27.9_+ 2.1 ng/ml. A repeat- 
ed measures A N C O V A  was conducted on peak values, 
using min 0 values as a covariate, revealing a trend to- 
wards a significant difference [F(1,3)= 3.19, P=0.0859] .  
Discussion 
There was significant dampening of  the cortisol response 
to nicotine following DEX administration, despite some- 
what  higher nicotine intake in that  session, indicating 
diminished sensitivity to nicotine as a result of  synthetic 
corticosteroid administration. The magnitude of  the 
stimulation of  cortisol by nicotine in the placebo condi- 
tion was nearly identical to that found under similar 
conditions in a recent study by Chiodera et al. (1984). 
Since A C T H  levels were not measured directly, it is not  
clear to what  extent this effect was mediated through 
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steroid inhibi tory control  mechanisms at the level o f  the 
hypophysis  (Cam et aI. 1979) o r  th rough  possible act ion 
o f  the synthetic cort icosteroid on nicotinic receptors at 
the level o f  the adrenal  cortex (Rubin  and  Warner  1975). 
There was also a trend towards  a significant correlat ion 
between cortisol boos t  for  the D E X  and placebo condi-  
tions, suggesting characterist ic individual differences in 
response to nicotine. 
These findings conf i rm and  extend to the h u m a n  lev- 
el the observat ion o f  cort icosteroid modu la t ion  o f  be- 
havioral  and physiological  sensitivity to nicotine in ani- 
mals (Freund et al. 1988 ; Pauly et al. 1988). The findings 
will now need to be replicated in a larger sample o f  
smokers  (and non-smokers) ,  using a variety o f  synthetic 
cort icosteroids and addit ional  physiological  and behav- 
ioral measures o f  sensitivity. The significance o f  the re- 
search is not  only that  it suggests mechanisms for  ex- 
plaining acute tolerance resulting f rom nicotine adminis-  
t rat ion bu t  also that  it predicts changes in sensitivity 
to nicotine in other  condit ions that  modi fy  cort icosteroid 
levels, such as physical  and  psychological  stress (Brenner 
et al. 1986; Pomerleau and Pomerleau 1989). 
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